
Profitability, historical returns, and peer comparisons.
According to Kailera Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -55.41%. This represents a change of -1435.21% compared to the average of 4.15% of the last 4 quarters.
The mean historical ROE of Kailera Therapeutics, Inc. over the last ten years is 41.79%. The current -55.41% ROE has changed -232.61% with respect to the historical average. Over the past ten years (40 quarters), KLRA's ROE was at its highest in in the March 2026 quarter at 18.25%. The ROE was at its lowest in in the June 2026 quarter at -9.95%.
Average
41.79%
Median
41.79%
Minimum
41.79%
Maximum
41.79%
Discovering the peaks and valleys of Kailera Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 41.79%
Minimum Annual Increase = 0%
Minimum Annual ROE = 41.79%
| Year | ROE | Change |
|---|
The current ROE of Kailera Therapeutics, Inc. (KLRA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
41.79%
5-year avg
41.79%
10-year avg
41.79%
Kailera Therapeutics, Inc.’s ROE is greater than Biomea Fusion, Inc. (-171.19%), greater than MBX Biosciences, Inc. Common Stock (-26.01%), greater than BioAge Labs Inc. (-28.99%), greater than MetaVia Inc. (-209.67%), greater than vTv Therapeutics Inc. (-6.27%), greater than Viking Therapeutics, Inc. (-117.35%), greater than Altimmune, Inc. (-31.41%), less than Oramed Pharmaceuticals Inc. (72.96%), greater than Fractyl Health, Inc. (-1625.88%), greater than NewAmsterdam Pharma Company N.V. (-38.33%),
| Company | ROE | Market cap |
|---|---|---|
| -171.19% | $45.44M | |
| -26.01% | $2.62B | |
| -28.99% | $210.08M | |
| -209.67% | $7.73M | |
| -6.27% | $97.70M | |
| -117.35% | $3.42B | |
| -31.41% | $395.84M | |
| 72.96% | $168.26M | |
| -1625.88% | $12.54M | |
| -38.33% | $2.35B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kailera Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kailera Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Kailera Therapeutics, Inc.'s ROE?
How is the ROE calculated for Kailera Therapeutics, Inc. (KLRA)?
What is the highest ROE for Kailera Therapeutics, Inc. (KLRA)?
What is the 3-year average ROE for Kailera Therapeutics, Inc. (KLRA)?
What is the 5-year average ROE for Kailera Therapeutics, Inc. (KLRA)?
How does the current ROE for Kailera Therapeutics, Inc. (KLRA) compare to its historical average?